Latest News

Tiziana Announces Initiation of a Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers

04 December 2019

London/New York, 4 December 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a clinical-stage biotechnology company focused on developing innovative therapeutics for inflammatory diseases and cancers, is pleased to announce initiation of a Phase I clinical trial...

Read more

Issue of equity and directorate change

20 November 2019

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

New York/London, 20 November 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...

Read more

Issue of convertible unsecured loan notes with warrants attached to raise £1,434,000

01 November 2019

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has raised £1,434,000 of finance by way of the issue of convertible unsecured loan notes (the "Loan Notes"), with warrants attached, for working capital purposes.

Read more

Change to ADS ratio

30 October 2019

Change to ADS ratio

Read more

Interim Results for the Six Months Ended 30 June 2019: Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

30 September 2019

London, 30 September 2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six...

Read more

Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers.

16 September 2019

A breakthrough approach for treatment of autoimmune and inflammatory diseases

Read more

Page 1 of 7 Next